Read More

Biodexa Announces $7M Of Gross Proceeds From Warrant Exercises And An Agreement Between The Company And Several Accredited Investors To Exercise Certain Existing Series E Warrants And Series F Warrants To Purchase Up To An Aggregate Of 4,358,322 ADSs

Biodexa Announces $7 Million of Gross Proceeds from Warrant ExercisesProceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant FundingBiodexa Pharmaceuticals PLC, (NASDAQ:BDRX),

BDRX